The BHMT-betaine methylation pathway epigenetically modulates oligodendrocyte maturation.
Animals
Betaine
/ metabolism
Betaine-Homocysteine S-Methyltransferase
/ antagonists & inhibitors
Brain
/ metabolism
Cells, Cultured
Chromatin
/ metabolism
DNA (Cytosine-5-)-Methyltransferases
/ metabolism
Epigenesis, Genetic
Gene Expression
/ drug effects
Histones
/ metabolism
Humans
Methionine
/ metabolism
Methylation
Multiple Sclerosis
/ genetics
Nitroprusside
/ pharmacology
Oligodendroglia
/ cytology
RNA Interference
RNA, Small Interfering
/ metabolism
Rats
SOXE Transcription Factors
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
11
2019
accepted:
08
04
2021
entrez:
11
5
2021
pubmed:
12
5
2021
medline:
13
10
2021
Statut:
epublish
Résumé
Research into the epigenome is of growing importance as a loss of epigenetic control has been implicated in the development of neurodegenerative diseases. Previous studies have implicated aberrant DNA and histone methylation in multiple sclerosis (MS) disease pathogenesis. We have previously reported that the methyl donor betaine is depleted in MS and is linked to changes in histone H3 trimethylation (H3K4me3) in neurons. We have also shown that betaine increases histone methyltransferase activity by activating chromatin bound betaine homocysteine S-methyltransferase (BHMT). Here, we investigated the role of the BHMT-betaine methylation pathway in oligodendrocytes. Immunocytochemistry in the human MO3.13 cell line, primary rat oligodendrocytes, and tissue from MS postmortem brain confirmed the presence of the BHMT enzyme in the nucleus in oligodendrocytes. BHMT expression is increased 2-fold following oxidative insult, and qRT-PCR demonstrated that betaine can promote an increase in expression of oligodendrocyte maturation genes SOX10 and NKX-2.2 under oxidative conditions. Chromatin fractionation provided evidence of a direct interaction of BHMT on chromatin and co-IP analysis indicates an interaction between BHMT and DNMT3a. Our data show that both histone and DNA methyltransferase activity are increased following betaine administration. Betaine effects were shown to be dependent on BHMT expression following siRNA knockdown of BHMT. This is the first report of BHMT expression in oligodendrocytes and suggests that betaine acts through BHMT to modulate histone and DNA methyltransferase activity on chromatin. These data suggest that methyl donor availability can impact epigenetic changes and maturation in oligodendrocytes.
Identifiants
pubmed: 33975330
doi: 10.1371/journal.pone.0250486
pii: PONE-D-19-31849
pmc: PMC8112889
doi:
Substances chimiques
Chromatin
0
Histones
0
RNA, Small Interfering
0
SOXE Transcription Factors
0
Nitroprusside
169D1260KM
Betaine
3SCV180C9W
Methionine
AE28F7PNPL
DNA (Cytosine-5-)-Methyltransferases
EC 2.1.1.37
Betaine-Homocysteine S-Methyltransferase
EC 2.1.1.5
Banques de données
Dryad
['10.5061/dryad.6t1g1jwx4']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250486Subventions
Organisme : NINDS NIH HHS
ID : R01 NS096148
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS097303
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
eNeuro. 2017 Mar 30;4(2):
pubmed: 28451635
J Neurosci. 2014 Mar 26;34(13):4453-65
pubmed: 24671992
Metab Brain Dis. 2018 Dec;33(6):1923-1934
pubmed: 30094804
Appl Physiol Nutr Metab. 2017 Nov;42(11):1228-1231
pubmed: 28715642
Neurotherapeutics. 2017 Oct;14(4):894-904
pubmed: 28948533
Cell Mol Neurobiol. 2018 May;38(4):783-795
pubmed: 28905149
FEBS Lett. 2006 May 29;580(13):2994-3005
pubmed: 16697371
Brain Res Brain Res Protoc. 2002 Aug;10(1):23-30
pubmed: 12379434
Epigenetics. 2020 Aug;15(8):871-886
pubmed: 32096676
Curr Neurol Neurosci Rep. 2014 Oct;14(10):485
pubmed: 25108747
J Clin Cell Immunol. 2013 Jul 31;4:
pubmed: 24273691
Cells. 2019 Oct 11;8(10):
pubmed: 31614602
Neurology. 2016 Mar 15;86(11):1014-21
pubmed: 26888980
Neurobiol Dis. 2010 Jul;39(1):47-52
pubmed: 19853663
Am J Clin Nutr. 1993 Jan;57(1):47-53
pubmed: 8416664
Eur J Clin Invest. 1996 Feb;26(2):167-70
pubmed: 8904527
Brain. 2008 Jul;131(Pt 7):1749-58
pubmed: 18515322
Environ Mol Mutagen. 2014 Apr;55(3):171-83
pubmed: 24449392
Neurochem Int. 2018 Jan;112:1-4
pubmed: 29080803
Am J Clin Nutr. 2008 Feb;87(2):424-30
pubmed: 18258634
BMC Res Notes. 2009 Dec 10;2:243
pubmed: 20003239
Cancer Cell. 2011 Nov 15;20(5):606-19
pubmed: 22094255
Iran Biomed J. 2012;16(2):84-9
pubmed: 22801281
FEBS J. 2016 Oct;283(20):3791-3806
pubmed: 27579714
J Neurol. 2007 Jan;254(1):115-7
pubmed: 17508146
Cold Spring Harb Perspect Biol. 2015 Jul 01;7(9):a020461
pubmed: 26134004
Nat Neurosci. 2008 Sep;11(9):1024-34
pubmed: 19160500
Glia. 2019 Apr;67(4):718-728
pubmed: 30793389
Nat Rev Neurosci. 2008 Nov;9(11):839-55
pubmed: 18931697
Eur J Pain. 2011 Jan;15(1):11-6
pubmed: 20584621
Clin Biochem. 2010 Jun;43(9):732-44
pubmed: 20346934
Glia. 2019 May;67(5):825-843
pubmed: 30730593
Cell Mol Neurobiol. 2017 Nov;37(8):1335-1348
pubmed: 28224237
Neurogenesis (Austin). 2017 Jan 31;4(1):e1270381
pubmed: 28203606
J Neurosci. 2015 Nov 11;35(45):15170-86
pubmed: 26558787
PLoS One. 2012;7(3):e33290
pubmed: 22479380
J Neurosci. 2015 Jan 7;35(1):352-65
pubmed: 25568127
Eur J Pharmacol. 2019 Jan 5;842:57-63
pubmed: 30393201
Neurosci Lett. 2014 Mar 6;562:75-8
pubmed: 24412677
J Biol Chem. 1999 Mar 19;274(12):7816-24
pubmed: 10075673
Nutrition. 2010 Nov-Dec;26(11-12):1170-5
pubmed: 20036517
Science. 2010 Nov 5;330(6005):779-82
pubmed: 21051629
J Immunol. 2018 Feb 15;200(4):1316-1324
pubmed: 29330324
J Biol Chem. 2011 May 27;286(21):18347-53
pubmed: 21454628
Annu Rev Pharmacol Toxicol. 2015;55:591-611
pubmed: 25340930
Adv Exp Med Biol. 2013;754:3-29
pubmed: 22956494
Neurosci Bull. 2015 Apr;31(2):271-3
pubmed: 25754147